Whiskey said:
Very good article that you found JA. I have read this all twice now and it is starting to sink in a little deeper.
I don't have any experience on this subject, but I was wondering if insulin, when used with GH would provide "near same" results as "GH and AAS," but not with insulin?
Also, would the frequency of insulin use differ when using it with GH. I once read that you should use it at X and X times, but I don't know if that was for bodybuilding purposes or not.
Once again, I don't have any experience with GH or insulin but have thought about it and doubt I will anytime soon, so if these are dumb questions I appologize ahead of time ;-)
Whiskey
From what I understand from ironmaster and others, exogenous GH alone suppresses insulin sensitivity to the extent that the use of exogenous insulin is almost essential if your goal is to get bigger AND leaner at the same time. This is evidently due to the insulin like action of IGF-1 in skeletal muscle. Insulin seems to be one of, if not the most anabolic hormones in the body. By blunting its action, GH impairs the anabolic effect of insulin.
This study highlights the effect "normal" dosing of GH has on insulin sensitivity however low doses of GH don't seem to effect IGFBP-1 levels that much. Maybe the idea of taken 2IU's/ed holds merit.
1: J Clin Endocrinol Metab. 2002 May;87(5):1989-95. Related Articles, Links
The effects of short-term administration of two low doses versus the standard GH replacement dose on insulin sensitivity and fasting glucose levels in young healthy adults.
Yuen K, Ong K, Husbands S, Chatelain P, Fryklund L, Gluckman P, Ranke M, Cook D, Rosenfeld R, Wass J, Dunger D.
University Department of Pediatrics, Addenbrooke's Hospital, Cambridge CB2 2QQ, United Kingdom.
GH has both diabetogenic and insulin-like actions. Supraphysiological GH doses are known to reduce insulin sensitivity (S(I)), but lower doses are less well studied. We therefore compared the effects of two physiological GH doses (intermediate, 0.0033 mg/kg x d; low, 0.0017 mg/kg x d) with the standard adult GH deficiency replacement dose (standard, 0.008 mg/kg x d) on S(I), beta-cell function, IGF-I, and IGF binding proteins (IGFBPs)-1 and -3 in healthy adults. Eleven healthy nonobese volunteers (4 males and 7 females, aged 21-38 yr) received 7 daily injections of the standard and intermediate GH doses, and 10 (5 males and 5 females, aged 21-38 yr) received the low dose. Fasting blood samples were collected daily (days 1-8). S(I) and beta-cell function were calculated using the Homeostasis model assessment.
All GH doses increased IGF-I and IGFBP-3 levels, with the standard dose inducing the greatest rise (P < 0.001). At day 2 vs. baseline, all three doses increased the IGF-I/IGFBP-3 ratio, but only the standard dose lowered IGFBP-1 levels (P = 0.03). The standard dose reduced S(I) (P = 0.01), whereas the intermediate dose increased S(I) (P < 0.005) and lowered fasting insulin levels (P < 0.01). The low dose did not modify S(I), but reduced fasting glucose levels (P < 0.0001) and increased beta-cell function (P = 0.001). Males demonstrated higher IGF-I and IGFBP-3 responsiveness to the standard dose than females. Males also showed greater increase in S(I) and decrease in fasting glucose levels on both intermediate and low doses. In conclusion, the metabolic effects of GH are dose- and gender-dependent. The standard adult GH deficiency replacement dose induced insulin resistance, whereas lower doses improved S(I), especially in males.
The low GH dose lowered fasting glucose levels and could represent the optimal dose to stimulate beta-cell function without compromising S(I) in insulin-resistant GH-deficient adults.
PMID: 11994330 [PubMed - indexed for MEDLINE]